[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Progen Pharmaceuticals Ltd (PGLA)

Progen Pharmaceuticals Ltd (PGLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Progen Pharmaceuticals Ltd LEVEL 18 101 COLLINS STREET MELBOURNE C3 3000

www.progen-pharma.com P: 61-7-3273-9133

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Progen Pharmaceuticals Ltd was incorporated on 1989 under the laws of the Commonwealth of Australia and domiciled in the State of Queensland. The Company is a biotechnology company. It is engaged in the discovery, development and commercialization of small molecule therapeutics for the treatment of cancer. The Company operates the Research and Development business segment in Australia. The Company focuses on dual mechanism anti-angiogenesis and anti-metastatic oncology products, which control tumor size and spread. The Company is subject to various laws, regulations, policies, guidelines and recommendations relating to such matters as safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the protection of the environment. Furthermore, there has been a general trend towards greater regulation of the pharmaceutical industry and its products.

Key Statistics

Overview:

Market Capitalization, $K 9,120
Shares Outstanding, K 55,290
% of Insider Shareholders 3.60%
% of Institutional Shareholders 0.00%

Financials:

Annual Sales, $ 2,390 K
Annual Net Income, $ -9,040 K

Growth:

1-Year Return 32.00%
3-Year Return -17.50%
5-Year Return -21.43%
5-Year Revenue Growth -33.05%
5-Year Earnings Growth -100.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 12/31/69
Earnings Per Share ttm 0.00
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

PGLA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % -378.24%
Debt/Equity 0.00
Price/Sales 3.83
Price/Cash Flow N/A
Price/Book 0.54
Book Value/Share 0.00
Interest Coverage 0.00
60-Month Beta 0.04
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.